solo para uso en investigación
Cat. No.S1135
| Dianas relacionadas | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Otros Antifolate Inhibidores | L-5-Methyltetrahydrofolate calcium Calcium N5-methyltetrahydrofolate |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| PANC-1 | Function Assay | 84 μM | 24 h | enhances EGFR, HER3 and AKT phosphorylation levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | enhances EGFR, HER3 and AKT phosphorylation levels | 22977607 | |
| PANC-1 | Function Assay | 84 μM | 24 h | enhances EGFR phosphorylated levels, and the protein levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | enhances EGFR phosphorylated levels, and the protein levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | induces S arrest (P<0.05) and decreases the number of cells in the G2/M phase | 22977607 | |
| PANC-1 | Growth Inhibition Assay | IC50=83.76±0.19 μM | 22977607 | |||
| BXPC-3 | Growth Inhibition Assay | IC50=39.86±1.68 μM | 22977607 | |||
| Jurkat | Growth Inhibition Assay | 48 h | proportion of live cells=76.7±4.3 % | 23840376 | ||
| DM-3 | Growth Inhibition Assay | 48 h | proportion of live cells=101.3±2.8 % | 23840376 | ||
| JL-1 | Growth Inhibition Assay | 48 h | proportion of live cells=98.2±2.2 % | 23840376 | ||
| ZL-34 | Growth Inhibition Assay | 48 h | proportion of live cells=95.7±6.5 % | 23840376 | ||
| STAV-FCS | Growth Inhibition Assay | 48 h | proportion of live cells=88.1±8.9 % | 23840376 | ||
| M-14-K | Growth Inhibition Assay | 48 h | proportion of live cells=81.8±12.9 % | 23840376 | ||
| STAV-AB | Growth Inhibition Assay | 48 h | proportion of live cells=64.4±21.8 % | 23840376 | ||
| LoVo | Function Assay | 0.05 μM | 72 h | DMSO | increases the percentage of cells in the S phase | 23959460 |
| HT-29 | Function Assay | 0.05 μM | 72 h | DMSO | increases the percentage of cells in the S phase | 23959460 |
| WiDr | Growth Inhibition Assay | 72 h | DMSO | IC50=0.019 ± 0.002 μM | 23959460 | |
| SW1116 | Growth Inhibition Assay | 72 h | DMSO | IC50=1.70 ± 0.03 μM | 23959460 | |
| HCT116 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.049 ± 0.013 μM | 23959460 | |
| SW620 | Growth Inhibition Assay | 72 h | DMSO | IC50=1.09 ± 0.01 μM | 23959460 | |
| LoVo | Growth Inhibition Assay | 72 h | DMSO | IC50=0.032 ± 0.002 μM | 23959460 | |
| HT-29 | Growth Inhibition Assay | 72 h | DMSO | IC50=10.07 ± 0.94 μM | 23959460 | |
| A549/PEM-16 | Growth Inhibition Assay | 96 h | IC50=51.45 μM | 24348854 | ||
| A549/PEM-6.4 | Growth Inhibition Assay | 96 h | IC50=23.39 μM | 24348854 | ||
| A549/PEM-1.6 | Growth Inhibition Assay | 96 h | IC50=5.03 μM | 24348854 | ||
| A549 | Growth Inhibition Assay | 96 h | IC50=1.35 μM | 24348854 | ||
| MSTO-211H | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50~0.04 μg/ml | 24378576 | |
| Y-meso14 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H290 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H226 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H1299 | Growth Inhibition Assay | IC50=1.84 μM | 24418519 | |||
| H1993 | Growth Inhibition Assay | IC50=0.17 μM | 24418519 | |||
| A549 | Function Assay | 0.1/0.3/0.5/1 μM | 24/48 h | DMSO | produces the formation of AVOs in a dose-dependent manner | 24626722 |
| A549 | Cell Viability Assay | 0.1/0.3/0.5/1 μM | 24/48 h | DMSO | inhibits cell viability dose and time dependently | 24626722 |
| MES04 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| MES01 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| H2452 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| H2052 | Growth Inhibition Assay | IC50=0.57±0.34 μM | 24714722 | |||
| 211H | Growth Inhibition Assay | IC50=0.07±0.01 μM | 24714722 | |||
| H28 | Growth Inhibition Assay | IC50=0.07±0.02 μM | 24714722 | |||
| PC9/GR | Function Assay | 4.94 μM | 72 h | increases p-AKT levels | 24840891 | |
| PC9/GR | Function Assay | 4.94 μM | 72 h | increases p-ERK levels | 24840891 | |
| PC9/GR | Apoptosis Assay | 4.94 μM | 72 h | induces 19.54﹪ apoptosis | 24840891 | |
| PC9 | Apoptosis Assay | 16 nM | 72 h | induces 14.54﹪ apoptosis | 24840891 | |
| PC9/GR | Function Assay | 4.94 μM | 72 h | induces S-phase arrest | 24840891 | |
| PC9 | Function Assay | 16 nM | 72 h | induces S-phase arrest | 24840891 | |
| PC9/GR | Growth Inhibition Assay | 72 h | IC50=4.94±0.440 μM | 24840891 | ||
| PC9 | Growth Inhibition Assay | 72 h | IC50=16.05±1.85 nM | 24840891 | ||
| A549 | Function Assay | 0.1/0.3/1 μM | 48 h | increases the ratio of S-phase population | 24847863 | |
| A549 | Apoptosis Assay | 0.1/0.3/1 μM | 48 h | induces apoptosis in a dose dependent manner | 24847863 | |
| A549 | Function Assay | 0.1/0.3/1 μM | 48 h | increases the level of phosphorylated Akt in a dose dependent manner | 24847863 | |
| A549 | Function Assay | 1 µM | 4/8/12/24/48 h | increases the level of phosphorylated Akt in a time dependent manner | 24847863 | |
| A549 | Function Assay | 5 μM | 8 h | increases Mcl-1 ubiquitination levels | 24991768 | |
| A549 | Apoptosis Assay | 2.5 μM | 48 h | induces apoptosis | 24991768 | |
| H1792 | Function Assay | 2.5/5/10 μM | 48 h | downregulates Mcl-1 | 24991768 | |
| A549 | Function Assay | 2.5/5/10 μM | 48 h | downregulates Mcl-1 | 24991768 | |
| H1792 | Function Assay | 2.5 μM | 48 h | induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage | 24991768 | |
| A549 | Function Assay | 2.5 μM | 48 h | induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage | 24991768 | |
| H1792 | Function Assay | 2.5/5/10 μM | 48 h | increases Noxa expression significantly | 24991768 | |
| A549 | Function Assay | 2.5/5/10 μM | 48 h | increases Noxa expression significantly | 24991768 | |
| A549 | Function Assay | 1 μM | 48 h | leads to mitochondrial dysfunction combined with simvastatin | 25096993 | |
| MSTO-211 | Function Assay | 1 μM | 48 h | leads to mitochondrial dysfunction combined with simvastatin | 25096993 | |
| A549 | Function Assay | 1 μM | 48 h | enhances intracellular ROS production combined with simvastatin | 25096993 | |
| MSTO-211 | Function Assay | 1 μM | 48 h | enhances intracellular ROS production combined with simvastatin | 25096993 | |
| A549 | Apoptosis Assay | 1 μM | 48 h | enhances caspase-dependent apoptosis combined with simvastatin | 25096993 | |
| MSTO-211 | Apoptosis Assay | 1 μM | 48 h | enhances caspase-dependent apoptosis combined with simvastatin | 25096993 | |
| A549 | Cell Viability Assay | 1 μM | 48 h | produces a synergistic inhibitory effect on the cell growth combined with simvastatin | 25096993 | |
| MSTO-211 | Cell Viability Assay | 1 μM | 48 h | produces a synergistic inhibitory effect on the cell growth combined with simvastatin | 25096993 | |
| H1299 | Cell Viability Assay | 1-1000 nM | 72 h | IC50=178 nM | 25145669 | |
| A549 | Cell Viability Assay | 1-1000 nM | 72 h | IC50=137 nM | 25145669 | |
| MG-63 | Cell Viability Assay | 0.01-100 μM | 72 h | inhibits cell viability dosedependently | 25152399 | |
| U20S | Cell Viability Assay | 0.01-100 μM | 72 h | inhibits cell viability dosedependently | 25152399 | |
| HepG3 | Function Assay | 10 μM | 48 h | upregulates phosphorylated (p-) MEK1/2 (Ser217/221) and p-ERK1/2 (Thr202/Tyr204) | 25446102 | |
| HepG3 | Function Assay | 0.1–100 μM | 48 h | activates cyto-protective autophagy | 25446102 | |
| HepG3 | Function Assay | 0.1–100 μM | 48 h | induces p62 downregulation as well as Beclin-1 and LC3B-II upregulation | 25446102 | |
| HepG2 | Apoptosis Assay | 0.1–100 μM | 72 h | induces apoptosis slightly at high concerntration | 25446102 | |
| HepG2 | Cell Viability Assay | 0.1–100 μM | 72 h | high concentrations of pemetrexed at (10/100 μM) only slightly inhibits HepG2 cell survival | 25446102 | |
| A459 | Apoptosis Assay | 4μM | 48 h | induces apoptosis | 25743822 | |
| A459 | Function Assay | 1/2/4 μM | 48 h | decreases the levels of p-Akt | 25743822 | |
| A459 | Function Assay | 1/2/4 μM | 24/48 h | induces G1 phase arrest in dose- and time dependent manner | 25743822 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=30﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=20﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=50﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=20﹪ | 25975637 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=20﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=10﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=30﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=10﹪ | 25975637 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=10﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=5﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=10﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=5﹪ | 25975637 | |
| A549 | Function Assay | 1 μM | 48 h | increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin | 26334320 | |
| MSTO-211H | Function Assay | 1 μM | 48 h | increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin | 26334320 | |
| A549 | Apoptosis Assay | 1 μM | 24 h | induces apoptosis cotreated with simvastatin | 26334320 | |
| MSTO-211H | Apoptosis Assay | 1 μM | 24 h | induces apoptosis cotreated with simvastatin | 26334320 | |
| A549 | Function Assay | 1 μM | 24 h | enhances autophagy cotreated with simvastatin | 26334320 | |
| MSTO-211H | Function Assay | 1 μM | 24 h | enhances autophagy cotreated with simvastatin | 26334320 | |
| A549 | Cell Viability Assay | 1 μM | 48 h | enhances simvastatin inhibited viability | 26334320 | |
| MSTO-211H | Cell Viability Assay | 1 μM | 48 h | enhances simvastatin inhibited viability | 26334320 | |
| KB | Function assay | IC50 = 0.03 μM | 18680275 | |||
| RT16 | Antiproliferative assay | IC50 = 0.042 μM | 18680275 | |||
| D4 | Antiproliferative assay | IC50 = 0.06 μM | 18680275 | |||
| KB | Antiproliferative assay | IC50 = 0.068 μM | 18680275 | |||
| IGROV1 | Antiproliferative assay | IC50 = 0.102 μM | 18680275 | |||
| PC43-10 | Antiproliferative assay | IC50 = 0.138 μM | 18680275 | |||
| IGROV1 | Antiproliferative assay | IC50 = 0.2 μM | 18680275 | |||
| D4 | Antiproliferative assay | IC50 = 0.254 μM | 18680275 | |||
| KB | Antiproliferative assay | IC50 = 0.327 μM | 18680275 | |||
| RT16 | Antiproliferative assay | IC50 = 0.388 μM | 18680275 | |||
| R2 | Antiproliferative assay | IC50 = 0.894 μM | 18680275 | |||
| KB | Function assay | 30 mins | IC50 = 0.03 μM | 19371039 | ||
| R2 | Function assay | Ki = 0.096 μM | 20085328 | |||
| R2 | Function assay | Ki = 1.54 μM | 20085328 | |||
| KB | Function assay | IC50 = 30 μM | 20085328 | |||
| R2 | Antiproliferative assay | 10 to 14 days | IC50 = 0.00494 μM | 21879757 | ||
| R2 | Antiproliferative assay | 96 hrs | IC50 = 0.0132 μM | 21879757 | ||
| RT16 | Antiproliferative assay | 96 hrs | IC50 = 0.042 μM | 21879757 | ||
| D4 | Antiproliferative assay | 96 hrs | IC50 = 0.06 μM | 21879757 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 21879757 | ||
| IGROV1 | Antiproliferative assay | 96 hrs | IC50 = 0.102 μM | 21879757 | ||
| PC43-10 | Antiproliferative assay | 96 hrs | IC50 = 0.138 μM | 21879757 | ||
| IGROV1 | Antiproliferative assay | 96 hrs | IC50 = 0.2 μM | 21879757 | ||
| D4 | Antiproliferative assay | 96 hrs | IC50 = 0.254 μM | 21879757 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.327 μM | 21879757 | ||
| RT16 | Antiproliferative assay | 96 hrs | IC50 = 0.388 μM | 21879757 | ||
| R2 | Antiproliferative assay | 96 hrs | IC50 = 0.894 μM | 21879757 | ||
| R2(VC) | Antiproliferative assay | 96 hrs | IC50 = 0.974 μM | 21879757 | ||
| R2 | Function assay | Ki = 0.094 μM | 22243528 | |||
| R2 | Function assay | Ki = 2.54 μM | 22243528 | |||
| R2 | Growth inhibition assay | 96 hrs | IC50 = 0.0132 μM | 24111942 | ||
| RT16 | Growth inhibition assay | 96 hrs | IC50 = 0.042 μM | 24111942 | ||
| D4 | Growth inhibition assay | 96 hrs | IC50 = 0.06 μM | 24111942 | ||
| KB | Growth inhibition assay | 96 hrs | IC50 = 0.068 μM | 24111942 | ||
| PC43-10 | Growth inhibition assay | 96 hrs | IC50 = 0.138 μM | 24111942 | ||
| D4 | Growth inhibition assay | 96 hrs | IC50 = 0.254 μM | 24111942 | ||
| KB | Growth inhibition assay | 96 hrs | IC50 = 0.327 μM | 24111942 | ||
| RT16 | Growth inhibition assay | 96 hrs | IC50 = 0.388 μM | 24111942 | ||
| MTXRII-OuaR2-4 | Growth inhibition assay | 96 hrs | IC50 = 0.894 μM | 24111942 | ||
| R2(VC) | Growth inhibition assay | 96 hrs | IC50 = 0.974 μM | 24111942 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.00994 μM | 24256410 | ||
| KB | Function assay | 30 mins | IC50 = 0.01174 μM | 24256410 | ||
| RT16 | Cytotoxicity assay | 96 hrs | IC50 = 0.0182 μM | 24256410 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.0223 μM | 24256410 | ||
| PC43-10 | Cytotoxicity assay | 96 hrs | IC50 = 0.0306 μM | 24256410 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.69 μM | 24256410 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 25234128 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 25234128 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.06 μM | 25234128 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.068 μM | 25234128 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 25234128 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.254 μM | 25234128 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.327 μM | 25234128 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.388 μM | 25234128 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.894 μM | 25234128 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.974 μM | 25234128 | ||
| KB | Function assay | 1 hr | IC50 = 0.01174 μM | 25602637 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 25602637 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 25602637 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.042 μM | 25602637 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 25602637 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 25602637 | ||
| R2(VC) | Cytotoxicity assay | 96 hrs | IC50 = 0.974 μM | 25602637 | ||
| KB | Cytotoxicity assay | 72 hrs | IC50 = 0.07 μM | 25668494 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.08 μM | 25668494 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 1.26 μM | 25668494 | ||
| R2/PCFT4 | Function assay | 2 mins | K = 0.044 μM | 26317331 | ||
| R2/PCFT4 | Function assay | 2 mins | K = 0.27 μM | 26317331 | ||
| KB | Antiproliferative assay | 72 hrs | IC50 = 0.07 μM | 27017552 | ||
| SW620 | Antiproliferative assay | 72 hrs | IC50 = 0.08 μM | 27017552 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 1.26 μM | 27017552 | ||
| KB | Function assay | 72 hrs | IC50 = 0.07 μM | 28830032 | ||
| SW620 | Antiproliferative assay | 72 hrs | IC50 = 0.09 μM | 28830032 | ||
| MCF7 | Antiproliferative assay | 72 hrs | IC50 = 0.65 μM | 28830032 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 29425443 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 29425443 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.06 μM | 29425443 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 29425443 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 29425443 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.254 μM | 29425443 | ||
| R2/PCFT4 | Function assay | 2 mins | Ki = 0.259 μM | 29425443 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.327 μM | 29425443 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.849 μM | 29425443 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.894 μM | 29425443 | ||
| R2(VC) | Growth inhibition assay | 96 hrs | IC50 = 0.974 μM | 29425443 | ||
| A549 | Antiproliferative assay | 24 hrs | IC50 = 3.31 μM | 29807332 | ||
| MDA-MB-231 | Antiproliferative assay | 24 hrs | IC50 = 3.85 μM | 29807332 | ||
| OVCAR3 | Antiproliferative assay | 24 hrs | IC50 = 6.9 μM | 29807332 | ||
| SGC7901 | Antiproliferative assay | 24 hrs | IC50 = 9.08 μM | 29807332 | ||
| KB | Function assay | 1 uM | 24 hrs | Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs | 18680275 | |
| R2 | Antiproliferative assay | Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 10 uM thymidine and 320 uM AICA | 21879757 | |||
| R2 | Antiproliferative assay | Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 60 uM adenosine | 21879757 | |||
| R2 | Function assay | Inhibition of GARFTase in chinese hamster R2 cells expressing human PCFT assessed as incorporation of [14C]glycine into [14C]formyl GAR in the presence of 4 uM azaserine | 21879757 | |||
| R2 | Function assay | 10 uM | Inhibition of human PCFT-mediated [3H]MTX uptake ectopically expressed in chinese hamster R2 cells at 10 uM at pH 5.5 to 7.2 | 21879757 | ||
| PC43-10 | Function assay | 10 uM | 2 mins | Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control | 21879757 | |
| KB | Function assay | 1 uM | 48 hrs | Inhibition of AICARFTase in human KB cells assessed as phosphorylated AMPK at 1 uM after 48 hrs by Western blot analysis | 24256410 | |
| KB | Cytotoxicity assay | 96 hrs | Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of adenosine/AICA/thymidine | 24256410 | ||
| KB | Cell cycle arrest assay | 1 uM | 48 hrs | Cell cycle arrest in human KB cells assessed as accumulation at G1/G0 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control | 24256410 | |
| KB | Function assay | 48 hrs | Inhibition of AICARFTase in human KB cells assessed as accumulation of ZMP after 48 hrs by HPLC analysis | 24256410 | ||
| R2/PCFT4 | Function assay | 0.5 uM | 5 mins | Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug level at 0.5 uM at 37 degC at pH 5.5 measured over 5 mins | 26317331 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| IGROV1 | Function assay | Effect on TS protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| IGROV1 | Function assay | Effect on DHFR protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| IGROV1 | Function assay | Effect on HSP90 protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 471.37 | Fórmula | C20H19N5Na2O6 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 150399-23-8 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | LY-231514 disodium | Smiles | C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+] | ||
|
In vitro |
Water : 94 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
TS
(Cell-free assay) 1.3 nM(Ki)
DHFR
(Cell-free assay) 7.2 nM(Ki)
GARFT
(Cell-free assay) 65 nM(Ki)
|
|---|---|
| In vitro |
Pemetrexed disodium muestra actividad antiproliferativa en células de leucemia CCRF-CEM, carcinoma de colon GC3/C1 y carcinoma ileocecal HCT-8 con IC50 de 25 nM, 34 nM y 220 nM, respectivamente. Un estudio reciente muestra que el cisplatino más este compuesto combinado con la administración del gen SOCS-1 muestra un efecto antitumoral por inhibición de la proliferación celular, la invasividad y la inducción de apoptosis en células MPM infectadas con un vector de adenovirus que expresa SOCS-1.
|
| Ensayo de quinasa |
Ensayos y métodos enzimáticos.
|
|
La actividad de la TS se evalúa utilizando un método espectrofotométrico, que implica el seguimiento del aumento de la absorbancia a 340 nm resultante de la formación del producto, 7,8-dihidrofolato. El tampón de ensayo contiene 50 mM de ácido N-tris[hidroximetil]metil-2-aminoetanosulfónico, 25 mM de MgC12, 6,5 mM de formaldehído, 1 mM de EDTA y 75 mM de 2-mercaptoetanol, pH 7,4. Las concentraciones de desoxiuridilato monofosfato, 6R-MTHF y hIS son de 100 μM, 30 μM y 30 nM (1,7 miliunidades/mL), respectivamente. A la concentración de 6R-MTHF, se ensayan una reacción no inhibida y seis concentraciones de inhibidor. Los valores de Ki app se determinan ajustando los datos a la ecuación de Morrison utilizando un análisis de regresión no lineal con la ayuda del programa ENZFITTER. Los valores de Ki se calculan utilizando la ecuación: Ki app= Ki(1 + [S]/Km), donde [S] es igual a 30 μM y Km es igual a 3 μM. La actividad de la DHFR se ensaya espectrofotométricamente monitorizando la desaparición de los sustratos NADPH y 7,8-dihidrofolato a 340 nm. La reacción tiene lugar a 25°C en 0,5 mL de tampón de fosfato de potasio 50 mM, que contiene 150 mM de KC1 y 10 nM de 2-mercaptoetanol, pH 7,5, y 14 nM (0,34 miliunidad/mL) de DHFR. La concentración de NADPH es de 10 μM y el 7,8-dihidrofolato se varía a 5, 10 o 15 μM. A cada concentración de 7,8-dihidrofolato, se ensayan una reacción no inhibida y siete concentraciones de inhibidor. El programa de microcomputadora ENZFITI'ER se utiliza para obtener los valores de Ki app ajustando los datos a la ecuación de Morrison mediante análisis de regresión no lineal. Ki app= Ki(1 + [S]/Km), donde [S] es igual a la concentración de 7,8-dihidrofolato utilizada y Km de 7,8-dihidrofolato es igual a 0,15 μM. La actividad de la GARFT se ensaya espectrofotométricamente monitorizando el aumento de la absorbancia resultante de la formación del producto 5,8-dideazafolato a 295 nm. El disolvente de reacción contiene 75 mM de HEPES, 20% de glicerol y 50 mM de a-tioglicerol, pH 7,5, a 25°C. Las concentraciones de sustratos y enzimas utilizadas son 10 μM de α,β-glicinamida ribonucleótido, 0-10 μM de ácido 10-formil-5,8-dideazafólico y 10 nM (1,9 miliunidades/mL) de GARFT. Los valores de Ki se calculan utilizando el programa de Mecanismo Enzimático del espectrofotómetro Beckman DU640, que utiliza análisis de regresión no lineal para ajustar los datos a la ecuación de Michaelis-Menten para la inhibición competitiva.
|
|
| In vivo |
En el xenoinjerto de carcinoma pulmonar no microcítico H460 humano, el Pemetrexed disodium produce un retraso del crecimiento tumoral (TGD) dependiente de la duración.
|
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | EGFR / p-EGFR AKT / p-AKT / GSK3β / p-GSK3β Topo IIα / Topo I / γH2AX / Cleaved PARP / Survivin p-Chk1 / Chk1 / Cyclin D / Cyclin E / p-Histone H3 / Histone H3 / Cyclin B1 / p-Cdc2 / Cdc2 |
|
30953548 |
| Immunofluorescence | p-AKT |
|
24847863 |
| Growth inhibition assay | Cell viability |
|
28719077 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT06378892 | Recruiting | Non Small Cell Lung Cancer Metastatic|ALK Gene Mutation |
Centro di Riferimento Oncologico - Aviano |
March 15 2024 | Phase 2 |
| NCT06010277 | Recruiting | NSCLC|Mesothelioma|Thymoma |
Amphia Hospital|Albert Schweitzer Hospital |
February 6 2023 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.